PMC:3605436 / 9237-9898 JSONTXT

{"project":"NEUROSES","denotations":[{"id":"T203","span":{"begin":8,"end":19},"obj":"PATO_0001727"},{"id":"T204","span":{"begin":368,"end":372},"obj":"PATO_0000573"},{"id":"T205","span":{"begin":380,"end":388},"obj":"PATO_0000040"}],"text":"Patient disposition and datasets analysed\nA total of 205 patients were screened and 10 patients were considered screening failures. All patients enrolled constituted the intention to treat population (ITT), (N = 195). A total of 31 withdrawals occurred over the trial, resulting in 164 patients completing the trial. The most common reasons were: adverse event, moved/long travel distance, informed consent withdrawn, antibodies against natalizumab and pregnancy/pregnancy wish (Fig. 1).\n10.1371/journal.pone.0058643.g001 Figure 1 Flow diagram of the TYNERGY trial.\nThe CONSORT flow diagram model showing enrolment, follow-up, and data analysis was applied.\n\nD"}